Dysmenorrhoea – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:23:35 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Dysmenorrhoea – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A study to compare how the body absorbs celecoxib oral suspension and celecoxib capsules in healthy adults for the treatment of acute pain. https://clinicaltrials.eu/trial/a-study-to-compare-how-the-body-absorbs-celecoxib-oral-suspension-and-celecoxib-capsules-in-healthy-adults-for-the-treatment-of-acute-pain/ Wed, 29 Apr 2026 15:08:58 +0000 https://clinicaltrials.eu/trial/a-study-to-compare-how-the-body-absorbs-celecoxib-oral-suspension-and-celecoxib-capsules-in-healthy-adults-for-the-treatment-of-acute-pain/ This study is designed to compare how the body absorbs and uses two different forms of the medication celecoxib. The research focuses on conditions such as acute pain, which is sudden and short-term pain, as well as dysmenorrhea, commonly known as painful menstrual cramps, and various musculoskeletal and connective tissue disorders involving the muscles and joints. The investigation will compare a liquid version of the medication, known as celecoxib oral suspension, against the standard Celebrex capsules. Additionally, some participants may receive heparin, a medication typically used to prevent blood clots, as part of their background care.

The purpose of the study is to evaluate the bioavailability, which refers to the amount of a drug that enters the bloodstream and becomes available to produce an effect, and to see how eating food influences this process. During the trial, participants will receive a single dose of the medication under different conditions. This includes periods where they have not eaten, known as a fasted state, and periods after consuming a meal, known as a fed state. By comparing these different scenarios, researchers can determine if the liquid form works similarly to the capsule form and how food intake affects the medication’s performance.

]]> Evaluation of Botulinum Toxin Injections for Women with Severe Primary Dysmenorrhea Unresponsive to First-Line Treatments https://clinicaltrials.eu/trial/evaluation-of-botulinum-toxin-injections-for-women-with-severe-primary-dysmenorrhea-unresponsive-to-first-line-treatments/ Wed, 29 Apr 2026 15:06:16 +0000 https://clinicaltrials.eu/trial/evaluation-of-botulinum-toxin-injections-for-women-with-severe-primary-dysmenorrhea-unresponsive-to-first-line-treatments/ This study is investigating a new treatment approach for severe primary dysmenorrhea, which is extremely painful menstrual periods without an identifiable underlying medical condition. The research focuses on intramyometrial botulinum toxin injections (injections into the muscle layer of the uterus) administered through hysteroscopy (a procedure that allows doctors to look inside the uterus) compared to placebo injections. The purpose is to evaluate whether this treatment can reduce pain in women who haven’t responded to standard treatments like hormonal therapy and pain medications.

The study is designed as a double-blind, randomized controlled trial, meaning neither the participants nor the researchers know who receives the actual treatment versus the placebo. Women participating in the study will undergo a procedure to receive either the botulinum toxin or placebo injections into their uterine muscle. They will then be followed for 6 months to assess changes in menstrual pain intensity, pain during intercourse, sexual function, quality of life, and other related symptoms.

Throughout the study, participants will complete various questionnaires about their pain levels, menstrual bleeding, quality of life, and overall impression of improvement. The main assessment will occur 3 months after the injection procedure to determine if participants experienced meaningful improvement in their symptoms.

]]> Study on the Effectiveness of Chaste Tree Extract (Vitex agnus-castus BNO 1095) for Women with Menstrual Cramps (Primary Dysmenorrhea) https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-chaste-tree-extract-vitex-agnus-castus-bno-1095-for-women-with-menstrual-cramps-primary-dysmenorrhea/ Wed, 29 Apr 2026 14:26:03 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-chaste-tree-extract-vitex-agnus-castus-bno-1095-for-women-with-menstrual-cramps-primary-dysmenorrhea/ This clinical trial is focused on studying the effects of a treatment for primary dysmenorrhea, which is a condition characterized by cramping pain in the lower abdomen that occurs just before or during menstruation. The treatment being tested is a herbal medicine called Vitex agnus-castus BNO 1095, which is derived from the chaste tree fruit. The study aims to determine if this treatment can help reduce the symptoms of primary dysmenorrhea in women.

Participants in the study will be randomly assigned to receive either the Vitex agnus-castus BNO 1095 treatment or a placebo. The study will last for three menstrual cycles, during which the effectiveness of the treatment will be assessed. The goal is to see if there is an improvement in the cramping pain experienced by participants who take the herbal medicine compared to those who receive the placebo.

The study will monitor the participants’ symptoms over the course of the treatment period to evaluate any changes in their condition. The main focus is to observe a reduction in the peak pelvic pain score and to ensure that there is no increase in the use of standard pain relief medication during the treatment. This trial is designed to provide valuable information on whether Vitex agnus-castus BNO 1095 can be an effective option for managing primary dysmenorrhea.

]]>